Management of Oral Mucositis
REZULTATY KLINICZNE:
Absence of undesired effects.
Absence of interruptions in radiochemotherapy treatment.
Absence of undesired effects.
Absence of interruptions in radiochemotherapy treatment.
Oral Mucositis in patients undergoing haematopoietic stem cell transplants HSCT
REZULTATY KLINICZNE:
Treated patients with Mucosamin Spray developed less severe mucositis. Treated patients with Mucosamin Spray resolved the mucositis in less time. Maximum pain, measured with VAS scale, was lower in patients treated with Mucosamin Spray.
Treated patients with Mucosamin Spray developed less severe mucositis. Treated patients with Mucosamin Spray resolved the mucositis in less time. Maximum pain, measured with VAS scale, was lower in patients treated with Mucosamin Spray.
Treatment of symptomatic Oral Mucositis in Patients Undergoing Haematopoietic Stem Cell Transplantation (HSCT)
REZULTATY KLINICZNE:
Treated patients with Mucosamin Spray developed less severe mucositis.
Treated patients with Mucosamin Spray resolved the mucositis in less time.
Maximum pain, measured with VAS scale, was lower in patients treated with Mucosamin Spray.
Treated patients with Mucosamin Spray developed less severe mucositis.
Treated patients with Mucosamin Spray resolved the mucositis in less time.
Maximum pain, measured with VAS scale, was lower in patients treated with Mucosamin Spray.
Prevention of Oral Mucositis in patients undergoing Haematopoietic Stem Cell Transplants
REZULTATY KLINICZNE:
Reduction of the onset of oral mucositis. Reduction of the severity of oral mucositis. The mouthwash in prevention and the spray in treatment are a valuable therapeutic aid for oral mucositis in patients undergoing HSCT.
Reduction of the onset of oral mucositis. Reduction of the severity of oral mucositis. The mouthwash in prevention and the spray in treatment are a valuable therapeutic aid for oral mucositis in patients undergoing HSCT.
Women treated with Vaginal Brachytherapy after surgery
REZULTATY KLINICZNE:
Application of Mucosamin® vaginal cream during VBT was shown to have clinical benefit for FIGO* stage I endometrial cancer patients who received adjuvant HDR-VBT following surgery.
It appears to reduce the severity of mucosal reactions.
Optimal resolution of actinic vaginitis symptoms.
Application of Mucosamin® vaginal cream during VBT was shown to have clinical benefit for FIGO* stage I endometrial cancer patients who received adjuvant HDR-VBT following surgery.
It appears to reduce the severity of mucosal reactions.
Optimal resolution of actinic vaginitis symptoms.
Burning Mouth Syndrome
REZULTATY KLINICZNE:
Significantly promote patients’ healing and compliance.
Reduce pain sensation.
A more frequent improvement in mucosal objectivity already in the short term.
Mucosamin seems improve the degree of satisfaction, especially among females.
Significantly promote patients’ healing and compliance.
Reduce pain sensation.
A more frequent improvement in mucosal objectivity already in the short term.
Mucosamin seems improve the degree of satisfaction, especially among females.
Investigate the efficacy of Radioderm® Spray in preventing
REZULTATY KLINICZNE:
Appearence of G1 cutaneous erythema in patient treated with Radioderm® Spray occurred at the 18th session on average compared to those treated with placebo (12th session on average). Radioderm® Spray helped delay the appearence of G1 cutaneous toxicity.
Appearence of G1 cutaneous erythema in patient treated with Radioderm® Spray occurred at the 18th session on average compared to those treated with placebo (12th session on average). Radioderm® Spray helped delay the appearence of G1 cutaneous toxicity.
